Genocea Biosciences Inc (NASDAQ:GNCA) investors woke up to a nice 14% pop in the value of their shares, after the herpes vaccine maker presented positive 12 month immunogenicity data from the Phase 2a trial of its genital herpes immunotherapy GEN-003.
This analysis shows that GEN-003 immunization results in the development of CD4+ polyfunctional T cells, which indicates that GEN-003 is stimulating a multi-faceted T cell immune response to genital herpes. The presentation also details the strong, antigen-specific antibody responses elicited by GEN-003 for up to 12 months post-dosing, consistent with its sustained effect on viral shedding and clinical disease at the same time point. Data were presented at theInfectious Disease Society of America (IDSA) annual meeting in New Orleans, Louisiana.
“These data provide strong evidence of clear and robust T and B cell immune responses that support the positive 12 month clinical results from the Phase 2a trial, which show that GEN-003 has a significant and durable effect on genital herpes viral shedding and clinical disease for at least 12 months after dosing,” said Jessica Baker Flechtner, Ph.D., chief scientific officer at Genocea. “We are particularly excited about the data showing the development of polyfunctional T cells, which are considered to deliver a more effective immune response than those T cells which secrete only one mediator. This immunological data once again demonstrates that GEN-003 can have a true biological effect against genital herpes and supports our confidence in its potential to become a cornerstone treatment for this serious disease.”
Twelve-month clinical data previously reported from this Phase 2a trial found that, for the 60 μg per protein / 50 μg of adjuvant dose, which has been selected as the best dose for Phase 3 trials, viral shedding was reduced by 66 percent vs. baseline (p < 0.0001). Significant clinical efficacy was also demonstrated at this dose with a 65 percent reduction in the genital lesion rate vs. baseline (p=0.003) and 30 percent of patients remaining lesion free for 12 months post dosing. These data show that a single course of injections with GEN-003 can result in similar outcomes to taking a year of daily oral antiviral therapy. (Original Source)
On the ratings front, Genocea has been the subject of a number of recent research reports. In a report issued on September 30, FBR analyst Christopher James reiterated a Buy rating on GNCA, with a price target of $17, which represents a potential upside of 372% from where the stock is currently trading. Separately, on September 29, Needham’s Alan Carr reiterated a Buy rating on the stock and has a price target of $15.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Christopher James and Alan Carr have a yearly average loss of 23.3% and a return of 5.9% respectively. James has a success rate of 22% and is ranked #4039 out of 4188 analysts, while Carr has a success rate of 40% and is ranked #476.
Genocea Biosciences, Inc. operates as a clinical stage biotechnology company, which discovers and develops novel vaccines to address infectious diseases. It uses its proprietary platform technology, antigen lead acquisition system to discover and develop novel vaccine candidates. Its products include GEN-001, GEN-002, GEN-003, GEN-004 and GEN-005.